Scientific article
OA Policy
English

Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial

Published inArthritis research & therapy, vol. 16, no. 5, 458
Publication date2014
Abstract

Calcium pyrophosphate deposition (CPPD) may cause severe arthropathy, major joint destruction and treatment options are limited. The aim of this study was to test the therapeutic efficacy of methotrexate (MTX) in chronic or recurrent CPPD arthropathy.

Citation (ISO format)
FINCKH, Axel et al. Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial. In: Arthritis research & therapy, 2014, vol. 16, n° 5, p. 458. doi: 10.1186/s13075-014-0458-4
Main files (1)
Article (Published version)
Identifiers
Journal ISSN1478-6354
668views
191downloads

Technical informations

Creation01/27/2015 3:26:00 PM
First validation01/27/2015 3:26:00 PM
Update time01/24/2025 2:34:34 PM
Status update01/24/2025 2:34:34 PM
Last indexation01/24/2025 2:42:34 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack